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Introduction
Mesenchymal stem cells (MSCs), also named multipotent 
mesenchymal stromal cells, are largely studied as new 
therapeutic tools for a number of clinical applications. 
Indeed, these cells have been shown to have diﬀ  eren  tia-
tion capacities as well as paracrine eﬀ  ects via the secre-
tion of growth factors, cytokines, antiﬁ  brotic or angio-
genic mediators [1]. A large body of studies also indicates 
that MSCs possess an immunosuppressive function both 
in vitro and in vivo. We review the present knowledge on 
the mechanisms underlying the immunomodulatory 
characteristics of MSCs and their applications in animal 
models of immune suppression or in clinics.
Defi  nition of mesenchymal stem cells
MSCs were initially isolated from bone marrow but are 
now shown to reside in almost every type of connective 
tissue [2]. MSCs are characterized as a heterogeneous 
popu  lation of cells that proliferate in vitro as plastic-
adher  ent cells able to develop as ﬁ  broblast  colony 
forming-units [3]. MSCs are distinguished from hemato-
poietic cells by being negative for the cell surface markers 
CD11b, CD14, CD34, CD45 and human leukocyte antigen 
(HLA)-DR but expressing CD73, CD90 and CD105. 
Importantly, the capacity to diﬀ   erentiate into multiple 
mesenchymal lineages including bone, fat and cartilage is 
used as a functional criterion to deﬁ  ne MSCs [4].
Immunosuppressive mechanisms of mesenchymal 
stem cells
Immunosuppressive function of mesenchymal stem cells 
requires preliminary activation
MSC-mediated immunosuppression requires preliminary 
activation of the MSCs by immune cells through the 
secretion of the proinﬂ  ammatory cytokine IFNγ, alone or 
together with TNFα, IL-1α or IL-1β [5,6]. Th  is  activation 
step has also been shown in vivo in a model of graft versus
host disease (GVHD) since recipients of IFNγ–/– T cells did 
not respond to MSC treatment and succumbed to GVHD 
[7]. Indeed, MSCs from mice deﬁ   cient for the IFNγ 
receptor 1 do not have immunosuppressive activity, 
highlighting the important role of IFNγ in this process [6].
Mesenchymal stem cellimmunosuppression is mediated 
by soluble factors
Although target cell–MSC interactions may play a role, 
the MSC-mediated immunosuppression mainly acts 
through the secretion of soluble molecules that are 
induced or upregulated following cross-talk with target 
cells. Among these factors, indoleamine 2,3-dioxygenase 
(IDO) has consistently been reported [8,9]. On stimu-
lation with IFNγ, this enzyme metabolizes tryptophan to 
kynurenin, causing depletion of local trypto  phan and 
accumulation of toxic breakdown products. IDO, however, 
exerts its eﬀ  ects mainly through the local accumulation 
of tryptophan metabolites rather than through trypto-
phan depletion [10]. Whereas the majority of studies 
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MSCs lacking both IFNγ receptor 1 and IDO still exerted 
important immunomodulatory activity [11]. Th  is 
observation may be explained at least in part by a recent 
study reporting that Toll-like receptors expressed on 
MSCs augment their immunosuppressive activity in the 
absence of IFNγ through an autocrine IFNβ signaling 
loop, which was dependent on protein kinase R and able 
to induce IDO [12]. Contrary to human MSCs, lack of 
IDO activity was constantly reported for murine MSCs 
[13,14].
Induction of inducible nitric-oxide synthase (iNOS) by 
murine MSCs and production of nitric oxide was sug-
gest  ed to play a major role in T-cell proliferation 
inhibition [15]. Nitric oxide is a gaseous bioactive com-
pound aﬀ  ecting macrophage and T-cell functions. iNOS 
is induced in mouse MSCs after activation by IFNγ and 
TNFα, IL-1α or IL-1β, and MSCs from iNOS–/– mice had 
a reduced ability to suppress T-cell proliferation [6] 
(Bouﬃ      C, Bony C, Courties G, Jorgensen C, Noël D, 
submitted). Th  e expression level of iNOS mRNA in 
human MSCs was minimal [14], however, and secretion 
of nitric oxide by human MSCs was undetectable (Bouﬃ    
C, Bony C, Courties G, Jorgensen C, Noël D, unpublished 
results). Indeed, diﬀ   erent mechanisms of immuno-
suppression exist in diﬀ  erent species since human MSCs 
employ IDO as a major eﬀ  ector molecule whereas nitric 
oxide plays a critical role in mouse MSCs [14].
Prostaglandin E2 (PGE2) has also been involved in the 
immunosuppressive activity of MSCs. PGE2 is a product 
of arachidonic acid metabolism that acts as a powerful 
immune suppressant, inhibiting T-cell mitogenesis and 
IL-2 production, and is a cofactor for the induction of 
T-helper (Th   ) type 2 lymphocyte activity. Production of 
PGE2 by MSCs is enhanced following TNFα or IFNγ 
stimulation, and its inhibition using speciﬁ  c inhibitors 
resulted in restoration of T-lymphocyte proliferation 
[16]. MSC-derived PGE2 was shown to act on 
macrophages by stimulating the production of IL-10 and 
on monocytes by blocking their diﬀ  erentiation toward 
dendritic cells (DCs) [17,18].
Another MSC-secreted factor, IL-6, has been reported 
to be involved in the inhibition of monocyte diﬀ  eren-
tiation toward DCs, decreasing their stimulation ability 
on T cells [13,19]. In parallel, the secretion of IL-6 by 
MSCs has also been reported to delay apoptosis of 
lympho  cytes and neutrophils [20,21].
Other mediators – such as transforming growth factor 
beta 1, hepatocyte growth factor, heme oxygenase 1 and 
leukemia inhibitory factor – were shown to be produced 
by MSCs upon activation [16,22-24]. Th   e production of 
HLA-G5 by MSCs has more recently been shown to 
suppress T-cell proliferation, as well as natural killer cell 
cytotoxicity and T-cell cytotoxicity, and to promote the 
generation of regulatory T (TREG) cells [25,26]. Cell 
contact between MSCs and activated T cells induced 
IL-10 production, which was essential to stimulate the 
release of soluble HLA-G5.
Any of these molecules alone does not lead to a 
complete abrogation of T-cell proliferation, indicating 
their nonexclusive role. Instead, MSC-mediated immuno-
regulation is the result of the cumulative action displayed 
by several molecules.
Suppressive eff  ects on immune cells
Both CD4+ and CD8+ T-lymphocyte proliferation stimu-
lated with mitogens or speciﬁ  c antigens is suppressed by 
MSCs. Suppression occurred with MSCs from autolo-
gous or allogeneic sources, indicating that it was not 
restricted by major histocompatibility complex (MHC) 
[27,28]. Inhibition of proliferation depends on the arrest 
of T cells in the G0/G1 phase of the cell cycle, indepen-
dently of apoptosis, but instead MSCs promote the 
survival of stimulated T cells [29,30]. MSCs alter other 
T-cell functions, such as the decrease of production of 
IFNγ, IL-2, and TNFα and the increase of IL-4 secretion 
[16]. MSCs are not targets of CD8+ cytotoxic T cells but 
they can suppress the cytotoxic eﬀ   ects of cytotoxic 
T  cells [31]. Finally, MSCs have been reported to 
promote, both in vitro and in vivo, the generation of 
CD4+CD25+ or CD8+ TREG cells with functional properties 
[32].  In vivo data, however, are contradictory [33,34]. 
Recent studies suggest that MSCs may induce a cytokine 
proﬁ   le shift in the Th  1/Th  2 balance toward the anti-
inﬂ  ammatory phenotype Th  2 [35,36] (Bouﬃ    C, Bony C, 
Courties G, Jorgensen C, Noël D, personal communi-
cation). Indeed, MSCs can suppress antigen-speciﬁ  c T-
cell proliferation and cytotoxicity as well as inducing 
anti-inﬂ  ammatory or TREG cells.
Most studies have reported that MSCs inhibit the 
proliferation of B cells that are activated with anti-
immunoglobulin antibodies, soluble CD40 ligand or 
cytokines [37]. Nevertheless, activated B cells became 
susceptible to the suppressive activity of MSCs in the 
presence of exogenously added IFNγ [5]. Th  e  suppressive 
eﬀ   ect of IFNγ was possibly related to its ability to 
stimulate the production of IDO by MSCs, which in turn 
suppressed the proliferative response of eﬀ  ector T cells. 
MSCs exert their suppressive eﬀ  ect on B-cell terminal 
diﬀ  erentiation through the release of humoral factor(s); 
they also increase B-cell viability while inhibiting 
proliferation, arresting B lymphocytes in the G0/G1 phase 
of the cell cycle [38,39]. Another study, however, reported 
that MSCs promoted proliferation and diﬀ  erentiation of 
transitional and naive B cells into immunoglobulin-
secreting cells, and strongly enhanced proliferation and 
diﬀ  erentiation of memory B-cell populations into plasma 
cells [40]. Again, diﬀ   erences in cell puriﬁ  cation 
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analysis may explain discrepancies between studies.
Myeloid DCs are the most potent antigen-presenting 
cells, essential in the induction of immunity and toler-
ance. During maturation, immature DCs acquire the 
expression of co-stimulatory molecules and upregulate 
the expression of MHC class I and class II molecules 
together with other cell surface markers such as CD11c, 
CD80, CD83 and CD86. MSCs inhibit in vitro the 
maturation of monocytes and CD34+ hematopoietic 
progeni  tor cells into DCs, as shown by a decreased cell-
surface expression of MHC class II and co-stimulatory 
molecules, as well as a decreased production of IL-12 and 
TNFα [16,19,41]. Th  is  eﬀ  ect is at least partially mediated 
via the secretion of IL-6 by activated MSCs [13,19] or 
PGE2, which was directly responsible for blocking DC 
maturation [18]. Th   ese studies suggest that MSCs might 
direct DC maturation toward an anti-inﬂ  ammatory or 
regulatory phenotype responsible for an attenuated T-cell 
response.
Natural killer cells exhibit cytolytic activity that mainly 
targets cells which lack expression of HLA class I 
molecules. Killing by natural killer cells is regulated by a 
balance of signals transmitted by activating and inhibi-
tory receptors interacting with HLA molecules on target 
cells. MSCs have been shown to suppress IL-2-driven or 
IL-15-driven natural killer cell proliferation, IFNγ 
produc  tion and cytotoxicity against HLA class I-express-
ing targets [42]. Some of these eﬀ  ects seem to depend on 
cell-to-cell contact and on the release of soluble factors, 
including transforming growth factor beta 1 and PGE2, 
suggesting the existence of diverse mechanisms for MSC-
mediated natural killer cell suppression.
Neutrophils are also important mediators of innate 
immunity responsible for microorganism killing via the 
production of reactive oxygen species. MSCs were shown 
to delay apoptosis of neutrophils through an IL-6-
mediated mechanism that was associated with the 
downregulation of reactive oxygen species [20]. Delayed 
apoptosis was thought to preserve the pool of neutrophils 
that will be rapidly available in response to infections. 
Recently, Nemeth and colleagues suggested that LPS and 
TNFα stimulated MSCs during sepsis to secrete high 
levels of PGE2, which in turn reprogrammed monocytes 
and macrophages to produce large amounts of IL-10. Th  e 
released IL-10 seemed to prevent neutrophils from 
migrating into tissues and causing oxidative damage, thus 
mitigating multiorgan damage [17]. Th   e results therefore 
suggest that MSCs may modulate the host innate 
response and improve survival by preventing sepsis.
Th  e various studies indicate that MSCs suppress the 
function of several immune cells; notably the prolifera-
tion of T lymphocytes, the DC maturation and the 
induction of anti-inﬂ   ammatory or TREG cells. Some 
mecha  nisms of immunomodulation have been 
reproduced by several groups, in particular the secretion 
of IDO, PGE2, nitric oxide and HLA-G5 (Figure  1). 
Diﬀ  erences in the secretome proﬁ  le – particularly for IDO 
and nitric oxide – exist between humans and mice, 
however, suggesting that several mechanisms are likely to 
be responsible for the various eﬀ  ects reported to date. 
Our recent data suggest that MSCs exert two levels of 
action (Bouﬃ    C, Bony C, Courties G, Jorgensen C, Noël 
D, personal communication). One level occurs locally via 
the secretion of mediators that inhibit the proliferation of 
immune cells at the vicinity of MSCs. Th   e second induces 
a systemic response, either an anti-inﬂ  ammatory  Th  2 
immune proﬁ  le or, in some instances, the generation of 
TREG cells.
Homing capacities
Th  e traﬃ   cking and homing properties of MSCs are of 
particular interest for clinical applications aiming at 
using non-invasive systemic cell administration to treat 
inﬂ   ammation. MSCs have been shown to express a 
variety of chemokines and chemokine receptors and can 
home to sites of inﬂ  ammation by migrating towards inﬂ  am-
matory chemokines and cytokines [43,44]. Depend  ing on 
Figure 1. Schematic representation of the interactions between 
mesenchymal stem cells and immune cells. After activation, 
mesenchymal stem cells secrete soluble mediators – such as nitric 
oxide (NO), prostaglandin (PGE2), indoleamine 2,3-dioxygenase (IDO), 
IL-6, and human leukocyte antigen (HLA)-G. Production of these 
mediators regulates the proliferation and function of a variety of 
immune cells as well as the induction of regulatory T (TREG) cells either 
directly or indirectly through the generation of immature dendritic 
cells (DC). NK, natural killer.
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is observed – which is probably due to diﬀ  erences in 
culture conditions and limitations in detection tech-
niques. Homing of cultured MSCs, however, is ineﬃ   cient 
compared with leukocytes. Th  is ineﬃ   ciency  has  been 
attributed to a lack of cell adhesion and chemokine 
receptors but also to the size of MSCs that promote 
passive cell entrapment and reduce traﬃ   cking  [45]. 
Together with the evidence that host MSCs can mobilize 
in response to inﬂ   ammation or injury, systemically 
infused MSCs are also frequently observed within the 
bone marrow or in injured tissues. Indeed, although the 
understanding of the underlying mechanisms is still 
required, accumulating evidence suggests that systemic 
infusion of MSCs may be used for immunosuppressive 
treatments of various disorders.
Therapeutic applications of mesenchymal stem cells
Th   e hypoimmunogenicity of MSCs supports their thera-
peutic interest in a variety of diseases related to allo-
reactive immunity or autoimmunity. Indeed, the poor 
immunogenicity of these cells demonstrated in vitro and 
in vivo favors the possible use of allogeneic MSCs in 
acute clinical conditions where the availability of 
suﬃ   cient numbers of cells is rapidly needed. Th   e use of 
autologous cells, however, may have therapeutic applica-
tions in autoimmune diseases or pathologies that allow 
enough time for isolation and in vitro expansion of 
MSCs. Th  e few clinical applications performed to date 
conﬁ  rm safety with a lack of major adverse side eﬀ  ects. 
Indeed, serial magnetic resonance imaging performed in 
226 patients who received MSCs for various ortho  pedic 
conditions showed no evidence of malignant transfor-
mation for a mean follow-up of 10.6 ± 7.3 months [46]. 
Accordingly, although some studies described the capacity 
of human MSCs to accumulate chromosomal instability in 
vitro, it was recently reported that, even though some 
aneuploidy was detected, MSCs showed progressive 
growth arrest and entered senescence without evidence of 
transformation either in vitro or in vivo [47]. Further 
studies are needed, however, to address the in vivo survival 
of MSCs, ectopic tissue formation and malignant 
transformation on a larger number of cell preparations.
Transplantation
One of the ﬁ  rst in vivo studies showed that systemic 
infusion of MSCs isolated from bone marrow prolonged 
the survival of allogeneic skin grafts from 7 to 11 days in 
baboons receiving MSCs [48]. Using a semi-allogeneic 
heart transplant mouse model, infusion of donor-
derived MSCs prolonged cardiac allograft survival 
through tolerance induction, which was due to 
CD4+CD25+Foxp3+ T REG cell expansion and impaired 
anti-donor Th   1 activity [49].
In hematopoietic stem cell (HSC) transplantation, 
MSCs may help reconstitution of the bone marrow 
stroma after chemoradiotherapy and enhance HSC 
engraft  ment. As early as 2000, autologous MSC infusion 
was shown to improve the outcome of HSC trans  plan-
tation in advanced breast cancer patients [50]. Infusion of 
allogeneic MSCs, contrary to syngeneic MSCs, has since 
been demonstrated to result in rejection of stem cell 
grafts in a murine model of allogeneic bone marrow 
transplantation [51]. Th   e results in animal models on the 
potential use of MSCs to prevent rejection of allogeneic 
grafts are conﬂ  icting (for a review, see [52]). In a more 
recent study, however, co-transplantation of donor MSCs 
with HLA-disparate CD34+ HSCs resulted in sustained 
hemato  poietic engraftment in 14 children without any 
adverse reaction, indicating that MSCs reduce the risk of 
graft failure in haplo-identical HSC transplant recipients 
[53].
MSC infusion may also be very helpful in cord blood 
transplantation where the limited dose of stem cells 
delays engraftment and favors graft failure. Th  is cell 
therapy approach has also been used as GVHD prophy-
laxis in HSC transplantation.
Graft versus host disease
Th  e most signiﬁ  cant results on the immunosuppressive 
eﬀ  ects of MSCs so far have been observed in the treat-
ment of acute GVHD after allogeneic stem cell trans-
plantation. GVHD occurring beyond 100 days after HSC 
transplantation is generally called chronic GVHD, which 
has to be distinguished from acute GVHD that includes 
persistent, recurrent, or late-onset acute GVHD.
Th  e  ﬁ  rst case of ex vivo expanded haplo-identical MSC 
injection in a patient with severe grade IV GVHD of the 
gut and liver resulted in a striking improvement of the 
disease [54]. A phase II study has since reported that 30 
out of 55 patients had a complete response and nine 
patients showed improvement, indicating that, irres-
pective of the donor, MSC infusion might be an eﬀ  ective 
therapy for patients with steroid-resistant, acute GVHD 
[55]. Another report on patients with leukemia, however, 
showed eﬀ  ective prevention of acute GVHD but a higher 
incidence of relapses in patients who were co-trans-
planted with MSCs and MHC-identical allogeneic HSCs 
[56]. Co-transplantation of third-party donor HSCs with 
cord blood transplants has been shown to overcome the 
limitation posed by low cellularity of cord blood units for 
unrelated transplants in adults. For optimization of this 
therapeutic approach, the risk of GVHD still has to be 
reduced. Th  e co-infusion of MSCs from the same HSC 
donors was therapeutically eﬀ   ective for severe acute 
GVHD but no signiﬁ  cant  diﬀ   erences in cord blood 
engraftment and incidence of GVHD were observed [57]. 
Th   e results indicate the therapeutic potential of MSCs for 
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control of safety issues.
Autoimmune diseases
Based on their ability to moderate T-cell proliferation 
and function, MSCs have also been proposed as a thera-
peutic option in the treatment of autoimmune diseases. 
Th  ey have therefore been tested in a variety of animal 
models of diabetes, experimental autoimmune encepha-
lo  myelitis, systemic lupus erythematosus or rheumatoid 
arthritis.
Contrasted results were reported in rheumatoid 
arthritis using the experimental collagen-induced arthritis 
model. We ﬁ  rst showed that injection of the allogeneic 
C3H10T1/2 MSC line did not reverse the disease score 
[58]. In the same model, however, a single injection of 
primary MSCs was shown to prevent the occurrence of 
severe arthritis, which was associated with a decrease in 
serum proinﬂ   ammatory cytokines [59,60]. Th  e use of 
human adipose-derived MSCs was eﬀ  ective in the xeno-
geneic collagen-induced arthritis model. Th  e  therapeutic 
eﬃ   cacy was associated with decreased antigen-speciﬁ  c 
Th  1/Th  17 cell expansion, enhanced secretion of IL-10 
and generation of CD4+CD25+FoxP3+ TREG cells with the 
capacity to suppress self-reactive T-eﬀ  ector  responses 
[61]. Another study reported no convincing increase of 
TREG cells in vivo despite in vitro evidence of T-cell 
inhibition by MSCs [62]. Our recent data with primary 
syngeneic and allogeneic MSCs indicate that MSCs may 
have a dual eﬀ  ect: locally, reducing the clinical signs of 
inﬂ  ammation in the joints, probably via the secretion of 
antiproliferative mediators; and systemically, by switch-
ing the polarization of the host response towards a Th  2 
immune proﬁ  le (Bouﬃ    C, Bony C, Courties G, Jorgensen 
C, Noël D, personal communication). Th  e divergent 
mechanistic results obtained from the various studies 
underline the complexity of the MSC-mediated immuno-
suppressive process and the diﬀ   erences that may be 
attributed to the various MSC species used [14] and to the 
diﬀ  erent techniques of MSC isolation and culture [7,59].
In the experimental autoimmune encephalomyelitis 
murine model of multiple sclerosis, MSCs were shown to 
decrease the clinical signs associated with demyelini  za-
tion when injected before or at the onset of the disease, 
demonstrating the therapeutic eﬃ     cacy of MSCs [34]. 
Th  is eﬀ  ect was associated with immune suppression of 
eﬀ  ector T cells leading to IL-2 reversible T-cell anergy. 
Subsequently, it was reported that MSCs inhibited T-cell 
activation with reduced IL-17 and TNFα levels via the 
secretion of CCL2 by MSCs [63].
MSC transplantation conferred signiﬁ  cant therapeutic 
eﬀ  ects in the systemic lupus erythematosus mouse model 
of lupus by reconstructing the osteoblastic niche and 
restoring immune homeostasis [64]. On the basis of these 
promising results, four treatment-refractory patients 
were treated with allogeneic MSCs. Th   e patients presented 
a stable 12-month to 18-month disease remission, show-
ing improvement in serologic markers and renal function 
[64]. Th   eir data showed that MSC infusion restored the 
Foxp3+  cell levels in both mice and systemic lupus 
erythematosus patients.
Development of autoimmune diabetes results from 
immune cell dysfunction to maintain peripheral and 
central tolerance. MSCs may therefore be helpful in 
regulating TREG/autoreactive T-cell balance. Th  e ﬁ  rst 
results were obtained in the NOD/SCID model of 
chemically induced diabetes using human MSCs. In the 
treated diabetic mice, an increase in pancreatic islets and 
beta cells producing insulin was detected with a few 
glomerular endothelial cells of human origin. Th  ere  was 
also a decrease in macrophage inﬁ  ltration, resulting in 
the prevention of pancreatic injury [65]. Th  e role of 
MSCs was ﬁ  rst suggested to induce the regeneration of 
endogenous insulin-secreting cells, and, second, to 
inhibit the T-cell-mediated immune responses against 
newly formed beta cells [66]. A shift of the host immune 
response toward Th  2-like responses was proposed to 
occur in treated NOD mice [67].
Conclusion
Overall, the current data indicate that MSCs represent a 
promising alternative strategy in the treatment of various 
immune-mediated diseases. Encouraging results have 
already been obtained from the clinics. Many questions 
remain to be addressed, however, in order to provide 
better ways to control and optimize the immune response 
for the beneﬁ   t of the patient. Th  is implies a better 
understanding of the underlying mechanisms of 
immuno  suppression as well as satisfying safety concerns 
as regards the in vivo survival, formation of ectopic tissue 
and malignant transformation.
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